• Aurinia Pharmaceuticals initiated PRESERVE, a Phase 4 study testing LUPKYNIS in combination with select biologics in lupus nephritis.
• Planned enrollment about 150 patients across about 50 US sites; primary endpoint is complete renal response at 6 months.
• Program targets improved renal outcomes versus current therapy, supporting LUPKYNIS positioning in a multi-agent treatment approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.